Oncology Business Management | Specialty

The OncLive Oncology Business Management condition center page is a comprehensive resource for news and expert insights on business-focused updates and topics in oncology practices, including diversity efforts, telehealth, gaps in care, payment models, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates and best practices with oncology business management.

FDA Proposes Policy Changes to Improve Mammography Quality Standards

March 28th 2019

The FDA has proposed amendments to key policies to modernize breast cancer screening and improve mammography services, in order to enable healthcare providers and patients to make more informed medical decisions

US Market Is Still Waiting for Biosimilars to Produce Meaningful Price Reductions

March 14th 2019

When the FDA approved its first biosimilar drug in 2015—filgrastim-sndz, for compromised white blood cell count—there was talk of the benefits of competition in the pharma industry; increased access to medications for patients; and, of course, the all-around savings. Four years later, those benefits haven’t been fully realized,

NCI Director Ned Sharpless to Be Named Acting FDA Commissioner

March 13th 2019

National Cancer Institute director Norman (Ned) E. Sharpless, MD, has been named as acting commissioner of the FDA once Scott Gottlieb, MD, leaves the regulatory agency in April 2019.

NCCN Guidelines Gain Traction Around the Globe

March 4th 2019

Global use of cancer management guidelines from the National Comprehensive Cancer Network has climbed rapidly in recent years.

Digital Pills May Be on the Horizon in Cancer Care

February 28th 2019

There have been efforts in recent years to improve patient adherence to oncology medications; now, oncologists may soon have 1 more tool in the form of digital pills.

Germline Variants Assume Prominent Role in Oncology Treatment Paradigm

February 27th 2019

Stunning technological advances in the ability to examine the molecular structure of human DNA have significantly reduced the time and costs associated with this process.

Median Cost of New Oncology Agents to Exceed $200,000 by 2023

February 26th 2019

The annual cost of new oncology drugs will continue to trend upward over the next 5 years, eventually breaching the $200,000 level.

A Game-Changing Year for NSCLC

February 26th 2019

Available Therapies for ALK-Rearranged NSCLC

February 26th 2019

Resistance Mechanisms in EGFR+ NSCLC

February 26th 2019

Osimertinib, the Standard for EGFR+ NSCLC

February 26th 2019

Molecular Testing for NSCLC in 2019

February 26th 2019

ADRIATIC Trial in Locally Advanced Small-Cell Lung Cancer

February 26th 2019

A Win for Small-Cell Lung Cancer: IMPOWER 133

February 26th 2019

Treatment Options for mNSCLC After Progression

February 26th 2019

CheckMate-227 and the Role of TMB in NSCLC

February 26th 2019

Looking at the IMpower Data in NSCLC

February 26th 2019

Choosing Therapy for Newly Diagnosed NonDriver NSCLC

February 26th 2019

Driver Mutations Trump PD-L1 Expression in Lung Adenocarcinoma

February 26th 2019

Biomarker Testing in Stage III NSCLC

February 26th 2019